Serum IGF-1 levels and its clinical significance in patients with unresectable or metastatic gastrointestinal stromal tumors before and after imatinib treatment
- Author:
- No author available
- Journal Title:
- Cancer Research and Clinic
- Issue:
- 7
- DOI:
- 10.3760/cma.j.issn.1006-9801.2012.07.001
- Key Word:
- 胃肠道间质肿瘤;胰岛素样生长因子Ⅰ;酶联免疫吸附测定;Gastrointestinal stromal tumors;Insulin-like growth factor Ⅰ;Enzyme-linked immunosorbent assay
Abstract： Objectives To explore the serum insulin-like growth factor-1 (IGF-1) levels in the patients with unresectable or metastatic gastrointestinal stromal tumors before and after imatinib treatment and to discuss its clinical significance. Methods The serum samples of 27 patients with unresectable or metastatic gastrointestinal stromal tumors were collected before imatinib treatment(before treatment group) and three months after imatinib treatment (after treatment group).The other serum samples were collected from 20 healthy volunteers who were accepting health examination (control group). The serum IGF-1 levels of the samples were determined by enzyme-linked immunosorbent assay (ELISA).Results The mean serum IGF-1 levels were significantly higher in before treatment group than in control controls [(463.61±120.98) ng/ml vs.(115.75±39.27) ng/ml, t=12.355,P=0.000)]. Three months after imatinib treatment,the mean serum IGF-1 levels were significantly lower in after treatment group than in before treatment group [(244.64±100.11)ng/ml vs. (463.61±120.98) ng/ml, t=7.582,P=0.000]. Conclusions Serum IGF-1 levels may help to judge therapeutic effect,progression,recurrence or metastasis of the gastrointestinal stromal tumor.
- [1]王林,李海刚,林敏玲,等.胃肠道间质瘤中IGF和IGFR的表达及意义[J].2008,(1).
- [2]胃肠道间质瘤中国专家组.胃肠道间质瘤诊断与治疗中国专家共识[J].2009,(5).
- [3]Kiemeney L,Johnsen NF,Rinaldi S,etc.Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition.[J].2007,16(6).
- [4]Maki RG,Brennan MF,van-der-Zwan SM,etc.Outcome of metastatic GIST in the era before tyrosine kinase inhibitors.[J].2007,14(1).
- [5]Verweij J,Casali PG,Zalcberg J,etc.Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.[J].2004,364(9440).
- [6]Baglietto L,English DR,Giles GG,etc.Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer.[J].2007,16(4).
- [7]Giles GG,Boyle P,MacInnis RJ,etc.Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer.[J].2006,15(6).
- [8]Eisenberg, B,Tarn, C,Godwin, AK,etc.Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors[J].2008,105(24).
- [9]Renehan AG,Minder C,O'Dwyer ST,etc.Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis.[J].2004,363(9418).
- [10]B, Valentinis,R, Baserga.IGF-I receptor signalling in transformation and differentiation.[J].2001,54(3).
- [11]C C, Kappel,M C, Velez-Yanguas,S, Hirschfeld,etc.Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth.[J].1994,54.
- [12]Jheri J, Dupart,Jonathan C, Trent,Ho-Young, Lee,etc.Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro.[J].2009,8.
- [13]Cellerino R,Bearzi I,Cascinu S,etc.Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients.[J].2008,19(7).
- [14]Cai KQ,Eisenberg B,von-Mehren M,etc.The insulin-like growth factor system as a potential therapeutic target in gastrointestinal stromal tumors.[J].2008,7(19).
- [15]U, Bergmann,H, Funatomi,M, Yokoyama,etc.Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles.[J].1995,55.